EnerTiva Observational Initiative
Observed Changes in Various Longevity Monitoring Tools in Patients on Diverse Interventions

We would like to investigate GLP-1 Inhibitor products for efficacy as longevity and healthspan promoting products. These measures include measures of weight loss, mood, activity, alertness, cognitive function, fatigue, inflammation, immune health, and clinical and blood-based evaluations of health and longevity.

Rapamycin Trial
Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL)

Rapamycin is an FDA-approved antifungal agent, most used to prevent organ transplant rejection. Rapamycin targets the mTOR signaling pathway, which is associated with many aging-related diseases.

MEARL is a double-blind, randomized, placebo-controlled trial. Notably, it is the first nationwide telemedicine trial and the first large-scale intervention trial on longevity. MEARL is proudly sponsored by EnerTiva and affiliated with the University of California.

Post-COVID-19 Trial
Pilot Study into Low Dose Naltrexone (LDN) and NAD+ for Treatment of Patients with Post-COVID-19

Proudly sponsored by AgelessRx, this double-blind placebo-controlled pilot study will assess the use of Low Dose Naltrexone (LDN) and NAD+ for the treatment of patients with post-COVID-19 (long-COVID-19).

EnerTiva will enroll over 60 people (must have had a positive test for SARS-CoV-2 1-4 months before enrollment) for a 12-week study. Patients will receive LDN and NAD+ treatment or a corresponding placebo tablet and patch (control group) for the 12-week duration.